CTI-1601
Phase 1Biologic
CTI-1601 is one of 27 biologic programs targeting Ataxia. It is currently in Phase 1.
1
Indications
4
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
34 competitors in Ataxia
#DrugCompanyPhaseTrials
1Rocaltrol
Alnylam PharmaceuticalsApproved
Actos
TakedaPhase 3
Plavix
SanofiPhase 3
Bayer Aspirin
BayerPhase 3
Diamox
TevaPhase 3
Chantix
PPrism Pharmaceuticals
Phase 3
Skyclarys
BiogenPhase 2
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 2
Ferriprox
Chiesi Farmaceutici S.p.A.Phase 2
Decadron
AAspen Global Incorporated
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ataxia4 trials
Show 1 more trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CTI-1601. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- LLarimar Therapeutics, Inc.